1. Home
  2. CTSO vs IPSC Comparison

CTSO vs IPSC Comparison

Compare CTSO & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTSO
  • IPSC
  • Stock Information
  • Founded
  • CTSO 1997
  • IPSC 2019
  • Country
  • CTSO United States
  • IPSC United States
  • Employees
  • CTSO N/A
  • IPSC N/A
  • Industry
  • CTSO Medical/Dental Instruments
  • IPSC Medicinal Chemicals and Botanical Products
  • Sector
  • CTSO Health Care
  • IPSC Health Care
  • Exchange
  • CTSO Nasdaq
  • IPSC Nasdaq
  • Market Cap
  • CTSO 61.3M
  • IPSC 58.1M
  • IPO Year
  • CTSO N/A
  • IPSC 2021
  • Fundamental
  • Price
  • CTSO $1.00
  • IPSC $0.51
  • Analyst Decision
  • CTSO Strong Buy
  • IPSC Strong Buy
  • Analyst Count
  • CTSO 3
  • IPSC 5
  • Target Price
  • CTSO $4.67
  • IPSC $4.67
  • AVG Volume (30 Days)
  • CTSO 83.4K
  • IPSC 461.7K
  • Earning Date
  • CTSO 05-08-2025
  • IPSC 03-19-2025
  • Dividend Yield
  • CTSO N/A
  • IPSC N/A
  • EPS Growth
  • CTSO N/A
  • IPSC N/A
  • EPS
  • CTSO N/A
  • IPSC N/A
  • Revenue
  • CTSO $37,739,531.00
  • IPSC $6,589,000.00
  • Revenue This Year
  • CTSO $9.20
  • IPSC N/A
  • Revenue Next Year
  • CTSO $11.64
  • IPSC N/A
  • P/E Ratio
  • CTSO N/A
  • IPSC N/A
  • Revenue Growth
  • CTSO 1.80
  • IPSC 194.81
  • 52 Week Low
  • CTSO $0.70
  • IPSC $0.51
  • 52 Week High
  • CTSO $1.61
  • IPSC $4.43
  • Technical
  • Relative Strength Index (RSI)
  • CTSO 44.00
  • IPSC 30.01
  • Support Level
  • CTSO $0.97
  • IPSC $0.54
  • Resistance Level
  • CTSO $1.08
  • IPSC $0.59
  • Average True Range (ATR)
  • CTSO 0.07
  • IPSC 0.05
  • MACD
  • CTSO -0.01
  • IPSC 0.00
  • Stochastic Oscillator
  • CTSO 17.53
  • IPSC 0.00

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.

Share on Social Networks: